Lab Sciences
Top stories summarized by our editors
4/17/2018

Health officials in Brazil are 10 million people short of the goal they set in January of vaccinating over 23 million people against yellow fever in the states of Bahia, Sao Paulo and Rio de Janeiro.

Full Story:
Medical Xpress
4/17/2018

Aptose Biosciences touted the efficacy of its experimental drug CG'806 as a treatment for specific blood cancers, with preclinical data showing CG'806 was 10 times as potent as Daiichi Sankyo's quizartinib and had up to 6,000 times greater potency compared with AbbVie's Imbruvica, or ibrutinib. The data were presented at the annual meeting of the American Association for Cancer Research.

4/16/2018

A partnership was reached by Illumina and Bristol-Myers Squibb to create and commercialize companion diagnostics for the pharmaceutical company's pipeline of oncology drugs. A diagnostic version of Illumina's TruSight Oncology 500 that will run on the NextSeq 550Dx is expected to be developed by the companies.

More Summaries:
Illumina, Bristol-Myers Squibb
4/16/2018

A study in The Lancet of 15,000 children in Tanzania found that piperonyl butoxide improved the ability of insecticide-treated bed nets to reduce malaria transmission. The prevalence of malaria was reduced by 44% in the first year of testing and 33% in the second, and the World Health Organization has recommended the new nets.

4/16/2018

Researchers from the University of Minnesota in Minneapolis evaluated health and quality of life outcomes for 176 living liver donors and found that 10% had complications that required intervention. The findings were published in the Journal of the American College of Surgeons.

4/16/2018

Surgeons at Memorial Hermann Hospital in Houston have developed an experimental therapy for severe brain trauma using infusions of autologous bone marrow cells. The therapy is being studied in a Phase II clinical trial.

More Summaries:
Memorial Hermann Hospital
4/13/2018

Researchers evaluated outcomes of 11 patients with chronic myeloid leukemia who had no history of cardiovascular disease and been treated with either imatinib or nilotinib and had never been treated with tyrosine kinase inhibitors. The study in the journal Cardiovascular Toxicity found that treatment with imatinib or nilotinib for 12 months was not associated with reduced cardiovascular function.

More Summaries:
imatinib, nilotinib
4/12/2018

EKF Diagnostics announced that its reagent-free DiaSpect Tm hemoglobin analyzer has received 510(k) clearance from the FDA and a CLIA waiver for use in clinical settings.

4/11/2018

Selinexor, Karyopharm Therapeutics' treatment for patients with multiple myeloma who have undergone at least three previous lines of therapy, was granted fast-track designation by the FDA. Top-line data from a study evaluating the drug is expected to be released by the end of the month.

4/11/2018

Illumina and Loxo Oncology will collaborate on the development and commercialization of a next-generation sequencing-based companion diagnostic that will have a pan-cancer indication under their newly announced global strategic partnership. A companion diagnostic version of Illumina's TruSight Tumor 170 that will operate on the NextSeq 550Dx platform will be validated by the companies as a Class III FDA-approved diagnostic with LOXO-292 for RET fusions or mutations and larotrectinib for NTRK fusions.

More Summaries:
Loxo Oncology, Illumina, Illumina